Categories: Chemotherapy, Stem Cell Transplantation
April 2009 Volume 7, Issue 4
Romuald Bellmann, MD, John D. Cleary, PharmD, FCCP, and Jaroslav Sterba, MD, PhD
Invasive fungal infections are an important cause of morbidity and mortality in critically ill and immunocompromised patients. Amphotericin B has remained the gold standard treatment for systemic fungal infections. The primary obstacle to amphotericin B therapy is its poor solubility and dose-related toxicities, especially renal impairment. As a result, newer lipid-based formulations of amphotericin B have been developed. This monograph compares available phamacokinetic, efficacy, and safety data for the 3 lipid-based formulations of amphotericin B, with reference to various patient populations. Potential causes of infusion-related reactions are described, and a premedication algorithm for the prevention of infusion-related reactions is developed.
Find what you're looking for by browsing or searching our online archives.
Browse by Category:
Search by keyword: